BIOSOLVE-IV Magmaris Swiss Satellite Registry

• Subject is ≥18 years of age
• Subject must be willing to sign a Patient Informed Consent
• Symptomatic coronary artery disease
• Subject with a maximum of two single de novo lesions in two different major epicardial vessels
• Target lesion length ≤ 21 mm by QCA or by visual estimation
• Target lesion stenosis >50% and \<100% by visual estimation, and TIMI flow ≥1.
• Subject is eligible for Dual Anti Platelet Therapy (DAPT)
• Reference vessel diameter between 2.7-3.7 mm by visual estimation, depending on the scaffold size used

Exclusion Criteria:

• Pregnant and/or breastfeeding females or females who intend to become pregnant during the time of the registry
• Known allergies to: Acetylsalicylic Acid (ASA), clopidogrel, heparin or any other anticoagulant /antiplatelet required for PCI, contrast medium, sirolimus, or similar drugs; or the scaffold materials including Magnesium, Yttrium, Neodymium, Zirconium, Gadolinium, Dysprosium, Tantalum that cannot be adequately pre-medicated
• Subjects on dialysis
• Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute ST elevation myocardial infarction (STEMI) within 72 hours prior to the index procedure. Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment
• Documented left ventricular ejection fraction (LVEF) ≤30% as documented within maximum 6 months prior to the procedure
• Heavily calcified or extremely tortuous lesions
• Bifurcation lesion requiring side branch intervention, if side branches >2 mm in diameter are involved
• Restenotic target lesion
• Thrombus in target vessel
• Target lesion is located in or supplied by a diseased (defined as vessel irregularity per angiogram and >20% stenosed lesion by visual estimation) arterial or venous bypass graft
• Left main coronary artery disease
• Ostial target lesion (within 5.0 mm of vessel origin)
• Target vessel (including side branches) has second lesion which requires treatment according to the investigator's discretion
• Unsuccessful pre-dilatation, defined as residual stenosis rate >20% by visual estimation and/or angiographic complications (e.g. distal embolization, side branch closure, extensive dissections)
• Planned surgery within 6 months of PCI unless dual antiplatelet therapy will be maintained
• Currently participating in another study and primary endpoint is not reached yet
• Planned interventional treatment of any non-target vessel within 30 days post procedure
• Planned intervention of the target vessel within 6-month after the index procedure